Advancing non-invasive healthcare through validated cfDNA solutions
Helping genomic healthcare professionals and researchers improve patient care.
See our range of liquid biopsy products below
Pre-analytical
Ensuring successful cell-free DNA analysis is our focus
Every sample is precious and to get the most out of your sample when evaluating cell-free DNA it is really critical to have processed your samples correctly from blood collection through to extracted cfDNA. Learn more about our Cell3™ Preserver blood tube and Cell3™ Xtract kit below.
Oncology
Efficient workflow enables confident calling of all ctDNA mutations
Nonacus are working with some of the brightest scientists and clinicians by providing a validated complete workflow for liquid biopsy analysis. With the ultimate goal of enabling better cancer care through earlier diagnosis, treatment stratification and monitoring.
Prenatal healthcare
Non-invasive prenatal testing requires sensitive, reproducible and easy to use products
Nonacus continues to develop innovative products to meet these exacting standards including tests for fetal rhesus-D genotyping, fetal fraction quantitation and single gene disorder testing.
Who we are
Designed by scientists, for scientists
We are formed of a committed group of biotechnology professionals with a combined 35 years experience in genomic healthcare. We understand the pressure on laboratories to deliver progress and our products are designed to get you there. Between us, we’ve got global experience of genomic healthcare from the NHS in the UK through to an international genome project.
What we stand for
True innovation that benefits patients
We translate research into routine diagnostic tools that directly benefit patients and scientists. Our non-invasive cell-free DNA solutions improve diagnostic accuracy as well as the patient’s experience. Our research & development team are constantly developing, validating and testing new cfDNA products.
Built for
We supply Universities with our cfDNA products to help them improve their understanding and research in non-invasive healthcare.
Leading hospitals have adopted our products to help improve patient care through the innovative use of cfDNA technology allowing for non-invasive diagnostics.
We partner with many leading laboratories to constantly innovate and push our cfDNA products further.
Read our latest insights
Can you use NGS panels to test for Tumor Mutational Burden?
Tumor Mutational Burden has been highlighted as a reliable predictor of immunotherapy response across multiple cancer types offering the potential to help guide treatment decisions for cancer patients. Typically whole exome and genome sequencing are used to assess TMB but NGS panels offer a far more cost-effective method making them a more feasible option for routine clinical use.
Read More
What is targeted next generation sequencing?
Targeted NGS focuses sequencing efforts on specific subsets of the genome. By concentrating on certain genomic regions, it is possible to achieve greater sensitivity and robust calling of low frequency variants.
Read More
Nonacus launches GALEAS® Bladder, a novel test for the non-invasive detection of bladder cancer
GALEAS® Bladder is a novel bladder cancer test providing a non-invasive, sample-to-report, molecular triage for patients with hematuria. The urine-based molecular biomarker, provides a highly sensitive test that can quickly and accurately detect bladder cancer and streamline diagnosis, thereby reducing the need for invasive cystoscopies.
Read More